Grand Pharmaceutical Group (HKG:0512) obtained approval to conduct a phase I/II clinical study of GPN01530 from the United States Food and Drug Administration (FDA), a Wednesday Hong Kong bourse filing said.
The trial will study the drug for the diagnosis of solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments